The United Kingdom and the United States have agreed to a key bilateral deal that will maintain zero tariffs on British drug products going into the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase spending on drugs through the NHS. This commitment guarantees that duties on these vital exports will stay at nothing for a timeframe of the next three years.
This development follows recent statements to hike import taxes on patented drug imports, with figures floated up to 100%.
"This deal between the UK bolsters the worldwide climate for new treatments and establishes much-needed equity to U.S.–U.K. medicine commerce," an announcement said.
Economic Significance
Pharmaceuticals constitute one of the UK's largest export categories to the America, which is by far the biggest destination for leading UK drugmakers.
Statistics indicate that in the 12 months prior to September, the UK exported drugs worth £11.1bn to the US. This value made up nearly one-fifth of total UK exports in that period.
"This agreement secures employment, increases investment and paves the way for the UK to emerge as a worldwide center for medical research," a minister commented.
Detailed NHS Changes
The agreement involves several notable commitments from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a target to increase total public funding on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must return to the NHS to control costs will be restricted at 15%. Previously, refunds were more than twenty percent.
Broader Context
The deal takes place against a long-running tension between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
These tensions were intensified by assertions that American patients were paying significantly more for the equivalent treatments than patients in the other developed nations.
Recently, several significant drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar investments have been announced toward projects in the United States.
One official publicly accepted that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had declined as a proportion of its resources over the last ten years.
